The results of multivariate analysis of time to engraftment, GVHD, and length of hospitalization
| . | BMT or PBSCT recipient . | CBT recipient . | Hazard ratio (95% CI)* . | P . |
|---|---|---|---|---|
| Recipients, n | 71 | 100 | — | — |
| Absolute neutrophil count higher than 0.5 × 109/L | 0.14 (0.10-0.22) | < .01 | ||
| No. of patients to achieve (%) | 69 (97) | 91 (91) | — | — |
| Median | 17 | 22 | — | — |
| Range | 10-35 | 16-46 | — | — |
| Platelet count higher than 20 × 109/L | 0.19 (0.13-0.28) | < .01 | ||
| No. of patients to achieve (%) | 68 (96) | 85 (85) | — | — |
| Median | 22.5 | 40 | — | — |
| Range | 12-122 | 13-99 | — | — |
| Platelet count higher than 50 × 109/L | 0.25 (0.17-0.36) | < .01 | ||
| No. of patients to achieve (%) | 67 (94) | 84 (84) | — | — |
| Median | 27 | 46 | — | — |
| Range | 13-453 | 25-263 | — | — |
| Acute GVHD | — | — | ||
| No. of evaluable patients† | 66 | 85 | — | — |
| Grade, no. (%) | — | — | ||
| 0 | 6 (9) | 4 (5) | — | — |
| I | 24 (36) | 30 (35) | — | — |
| II | 23 (35) | 45 (53) | — | — |
| III | 8 (12) | 4 (5) | — | — |
| IV | 5 (8) | 2 (2) | — | — |
| II-IV | 36 | 51 | 1.09 (0.71-1.68) | .69 |
| III-IV | 13 | 6 | 0.38 (0.15-0.95) | .04 |
| Patients treated with steroids | 28 | 18 | 0.25 (0.13-0.50) | < .01 |
| Chronic GVHD | — | — | ||
| No. of evaluable patients‡ | 55 | 82 | — | — |
| Limited + extensive | 49 | 73 | 1.43 (0.95-2.14) | .09 |
| Extensive | 30 | 23 | 0.49 (0.29-0.85) | .01 |
| Length of hospitalization | 0.73 (0.50-1.06) | .10 | ||
| No. of evaluable patients | 59 | 83 | — | — |
| Median | 89 | 121 | — | — |
| Range | 39-355 | 58-608 | — | — |
| . | BMT or PBSCT recipient . | CBT recipient . | Hazard ratio (95% CI)* . | P . |
|---|---|---|---|---|
| Recipients, n | 71 | 100 | — | — |
| Absolute neutrophil count higher than 0.5 × 109/L | 0.14 (0.10-0.22) | < .01 | ||
| No. of patients to achieve (%) | 69 (97) | 91 (91) | — | — |
| Median | 17 | 22 | — | — |
| Range | 10-35 | 16-46 | — | — |
| Platelet count higher than 20 × 109/L | 0.19 (0.13-0.28) | < .01 | ||
| No. of patients to achieve (%) | 68 (96) | 85 (85) | — | — |
| Median | 22.5 | 40 | — | — |
| Range | 12-122 | 13-99 | — | — |
| Platelet count higher than 50 × 109/L | 0.25 (0.17-0.36) | < .01 | ||
| No. of patients to achieve (%) | 67 (94) | 84 (84) | — | — |
| Median | 27 | 46 | — | — |
| Range | 13-453 | 25-263 | — | — |
| Acute GVHD | — | — | ||
| No. of evaluable patients† | 66 | 85 | — | — |
| Grade, no. (%) | — | — | ||
| 0 | 6 (9) | 4 (5) | — | — |
| I | 24 (36) | 30 (35) | — | — |
| II | 23 (35) | 45 (53) | — | — |
| III | 8 (12) | 4 (5) | — | — |
| IV | 5 (8) | 2 (2) | — | — |
| II-IV | 36 | 51 | 1.09 (0.71-1.68) | .69 |
| III-IV | 13 | 6 | 0.38 (0.15-0.95) | .04 |
| Patients treated with steroids | 28 | 18 | 0.25 (0.13-0.50) | < .01 |
| Chronic GVHD | — | — | ||
| No. of evaluable patients‡ | 55 | 82 | — | — |
| Limited + extensive | 49 | 73 | 1.43 (0.95-2.14) | .09 |
| Extensive | 30 | 23 | 0.49 (0.29-0.85) | .01 |
| Length of hospitalization | 0.73 (0.50-1.06) | .10 | ||
| No. of evaluable patients | 59 | 83 | — | — |
| Median | 89 | 121 | — | — |
| Range | 39-355 | 58-608 | — | — |
CI indicates confidence interval; GVHD, graft-versus-host disease; and —, not applicable.
The hazard ratio is for cord blood transplantation compared with bone marrow or peripheral blood stem-cell transplantation.
Acute GVHD was evaluated in patients surviving 21 days or longer after transplantation with evidence of engraftment.
Chronic GVHD disease was evaluated in patients surviving 100 days or longer after transplantation with engraftment.